Skip to nav Skip to content

Clinical Trial Search

300 Clinical Trials Found

Clinical Trial 23303

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Disease Site: Prostate
PI: Yamoah, Kosj

Clinical Trial 21193

Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 21459

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Disease Site: Colon
PI: Imanirad, Iman

Clinical Trial 20894

Acalabrutinib for Chronic Graft-versus-Host Disease
Disease Site: Unknown Sites
PI: Pidala, Joseph

Clinical Trial 21340

A First-In-Human, Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 With or Without Obinutuzumab Pre-treatment, and ST-067 in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Disease Site: Any Site, Breast, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin
PI: Tarhini, Ahmad

Clinical Trial 21027

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
Disease Site: Lung, Non small cell lung cancer
PI: Creelan, Benjamin

Clinical Trial 21673

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety ofHER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)
Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 90016

Disease Site: Other Hematopoietic
PI: Sandoval-Sus, Jose

Clinical Trial 21731

A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Disease Site: Melanoma, skin
PI: Khushalani, Nikhil

Clinical Trial 21559

Disease Site: Prostate
PI: Zhang, Jingsong

Clinical Trial 21416

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Disease Site: Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 21117

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Disease Site: Kidney
PI: Chahoud, Jad